Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement